Compare Amgen, Inc. (AMGN) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Kyndryl Holdings Inc — how do they compare? Amgen, Inc. trades at $356.83 (market cap $196.12B), while Kyndryl Holdings Inc trades at $12.48 (market cap $2.64B). The key difference: Amgen, Inc. is far larger — about 74.3× Kyndryl Holdings Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | KD | |
|---|---|---|
Market Cap | $196.12B | $2.64B |
Sector | Health | Technology |
52-Week High | $388.16 | $39.78 |
52-Week Low | $271.18 | $10.59 |
Enterprise Value | $241.41B | $4.97B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Kyndryl Holdings (KD) trades at $11.97, down 0.83% on the day, with technical indicators signaling a bearish trend. The company reported revenue of $15.06B in 2025, achieving a net income of $252M after three years of losses. Recent news includes leadership changes and legal investigations, while analyst consensus is mixed with a $14.33 price target. Cash flow improved to a net positive $236M in 2025, though debt levels remain elevated.
The outlook is cautious; profitability improvements and strategic partnerships offer potential upside, but legal risks and recent earnings misses pose significant challenges. Investors should weigh the low P/E of 14.08 against ongoing operational and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
